In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Dalmau, Judith ^a   Codoñer, Francisco M ^a,b   Erkizia, Itziar ^a   Pino, Maria ^a   Pou, Christian ^a   Paredes, Roger ^a   Clotet, Bonaventura ^a   Martinez Picado, Javier ^a,c   Prado, Julia G ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTEGRASE; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VIRUS DNA;

AMPLICON; ARTICLE; CASE REPORT; CONTROLLED STUDY; DEEP PYROSEQUENCING; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC DISTANCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INTERMETHOD COMPARISON; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PHYLOGENETIC TREE; PLASMA; PYROSEQUENCING; VIRAL TROPISM; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; BLOOD; CYTOLOGY; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MONONUCLEAR CELL; PHYLOGENY; PREDICTIVE VALUE; REPRODUCIBILITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DNA, VIRAL; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PHENOTYPE; PHYLOGENY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 84857662091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032714     Document Type: Article

References (42)

1. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
5. Preston BD, Poiesz BJ, Loeb LA, (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171.
6. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
7. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
8. Honeyborne I, Codoner FM, Leslie A, Tudor-Williams G, Luzzi G, et al. (2010) HLA-Cw*03-restricted CD8+ T-cell responses targeting the HIV-1 gag major homology region drive virus immune escape and fitness constraints compensated for by intracodon variation. J Virol 84: 11279-11288.
9. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: 453-459.
10. Peyerl FW, Barouch DH, Letvin NL, (2004) Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes. Viral Immunol 17: 144-151.
11. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
12. Larder BA, Kemp SD, (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
13. Irshad M, Ansari MA, Singh A, Nag P, Raghvendra L, et al. (2010) HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment. Hepatogastroenterology 57: 1529-1538.
14. Jerzak GV, Bernard K, Kramer LD, Shi PY, Ebel GD, (2007) The West Nile virus mutant spectrum is host-dependant and a determinant of mortality in mice. Virology 360: 469-476.
15. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R, (2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439: 344-348.
16. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
17. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, et al. (2005) Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 79: 9006-9018.
18. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, et al. (2010) Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 88: 281-286.
19. Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, et al. (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One 5: e12303.
20. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, et al. (2010) Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5: e11345.
21. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 203: 237-245.
22. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. Jama 305: 1327-1335.
23. Borderia AV, Lorenzo-Redondo R, Pernas M, Casado C, Alvaro T, et al. (2010) Initial fitness recovery of HIV-1 is associated with quasispecies heterogeneity and can occur without modifications in the consensus sequence. PLoS One 5: e10319.
24. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, et al. (1993) Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118: 681-688.
25. Richman DD, Bozzette SA, (1994) The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169: 968-974.
26. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR, (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-628.
27. Dalmau J, Puertas MC, Azuara M, Marino A, Frahm N, et al. (2009) Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis 48: 229-238.
28. Buzon MJ, Dalmau J, Puertas MC, Puig J, Clotet B, et al. (2010) The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. Aids 24: 17-25.
29. Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor-Williams G, et al. (2010) Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate. J Virol 84: 492-502.
30. Kusumi K, Conway B, Cunningham S, Berson A, Evans C, et al. (1992) Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol 66: 875-885.
31. Voronin Y, Chohan B, Emerman M, Overbaugh J, (2007) Primary isolates of human immunodeficiency virus type 1 are usually dominated by the major variants found in blood. J Virol 81: 10232-10241.
32. Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, et al. (2008) HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis 197: 1011-1015.
33. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
34. Yuste E, Borderia AV, Domingo E, Lopez-Galindez C, (2005) Few mutations in the 5′ leader region mediate fitness recovery of debilitated human immunodeficiency type 1 viruses. J Virol 79: 5421-5427.
35. Abbate I, Rozera G, Tommasi C, Bruselles A, Bartolini B, et al. (2010) Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect 17: 725-731.
36. Raymond S, Delobel P, Mavigner M, Cazabat M, Encinas S, et al. (2010) CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. Aids 24: 2305-2312.
37. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
38. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, et al. (1997) Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71: 7478-7487.
39. Posada D, (2008) jModelTest: phylogenetic model averaging. Mol Biol Evol 25: 1253-1256.
40. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
41. Villena C, Prado JG, Puertas MC, Martinez MA, Clotet B, et al. (2007) Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J Virol 81: 4713-4721.
42. Prado JG, Honeyborne I, Brierley I, Puertas MC, Martinez-Picado J, et al. (2009) Functional consequences of human immunodeficiency virus escape from an HLA-B*13-restricted CD8+ T-cell epitope in p1 Gag protein. J Virol 83: 1018-1025.